Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Hinge Health, Inc. Class A (HNGE – Research Report), Exelixis (EXEL – Research Report) and Natera (NTRA – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hinge Health, Inc. Class A (HNGE)
Truist Financial analyst Jailendra Singh reiterated a Buy rating on Hinge Health, Inc. Class A today. The company’s shares closed last Wednesday at $49.69.
According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of
Hinge Health, Inc. Class A has an analyst consensus of Strong Buy, with a price target consensus of $67.53, representing a 37.7% upside. In a report issued on December 7, TR | OpenAI – 4o also upgraded the stock to Buy with a $56.00 price target.
See the top stocks recommended by analysts >>
Exelixis (EXEL)
In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on Exelixis. The company’s shares closed last Wednesday at $41.07.
According to TipRanks.com, Goonewardene is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Exelixis is a Moderate Buy with an average price target of $43.90, implying a 4.4% upside from current levels. In a report issued on December 5, Morgan Stanley also maintained a Buy rating on the stock with a $45.00 price target.
Natera (NTRA)
According to TipRanks.com, Brennan is a 5-star analyst with an average return of
Natera has an analyst consensus of Strong Buy, with a price target consensus of $234.31, which is a -0.5% downside from current levels. In a report issued on December 9, TR | OpenAI – 4o also upgraded the stock to Buy with a $266.00 price target.
